⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GILD News
Gilead Sciences Inc
U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs
globenewswire.com
BMY
GILD
JNJ
SNY
TAK
AMGN
AZN
LLY
MRK
PFE
REGN
VRTX
ABBV
ALNY
AMTX
BIIB
BMRN
CRSP
EXAS
INCY
IONS
JAZZ
NTLA
PTC
RGEN
XOM
Metabolon's Metabolomics Platform Enables Largest Metabolomic Analysis to Date in CAR T-Cell Therapy, Revealing New Insights into Severe Neurotoxicity USA - English India - English
prnewswire.com
GILD
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
businesswire.com
GILD
Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options
businesswire.com
GILD
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
CAR T-Cell Therapy Market worth $13.78 billion by 2031 | MarketsandMarkets™
prnewswire.com
BMY
GILD
JNJ
CRSP
ALLO
CART
World-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors
prnewswire.com
GILD
AZN
BMY
ABBV
BCL-2 Inhibitors Market Poised for Robust Growth During the Forecast Period (2025-2034) as Oncology Pipelines Expand | DelveInsight
prnewswire.com
ABBV
AMGN
AZN
BMY
GILD
JNJ
LLY
MRK
NVS
PFE
SNY
TMO
Terray’s New EMMI Predict Model Sets an Industry Performance Standard – Delivering Best-In-Class Accuracy, 26x Faster
businesswire.com
GILD
Xilio Therapeutics Announces Pricing of Underwritten Offering
globenewswire.com
XLO
GILD